Evidence map›Paper›PMID 39289947›Full record

ArticleCurrent drug delivery2025

Enhanced Therapeutic Potential of Liposome-Coated Bushen Jianpi Recipe for Hepatocellular Carcinoma.

Siqi Feng, Yi Zhong, Yabin Li, Shiying Li, Yun Li, Zhangjie Zhou, Zhonghua Wu, Tingting Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siqi FengShanghai University of Traditional Chinese Medicine, Shanghai, Affiliated City College of Traditional Chinese and Western Medicine, China.
Yi ZhongDepartment of Oncology, Shanghai TCM-integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yabin LiCollege of Life Science and Technology, Tongji University, Shanghai, China.
Shiying LiShanghai University of Traditional Chinese Medicine, Shanghai, Affiliated City College of Traditional Chinese and Western Medicine, China.
Yun LiDepartment of Oncology, Shanghai TCM-integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhangjie ZhouDepartment of Oncology, Shanghai TCM-integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhonghua WuShanghai University of Traditional Chinese Medicine, Shanghai, Affiliated City College of Traditional Chinese and Western Medicine, China.
Tingting WuDepartment of Oncology, Shanghai TCM-integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

Chinese Medicine Research Project of Hongkou District Health and Wellness Committee HKQGYQY-ZYY-2022-17Hongkou District Health Committee Traditional Chinese Medicine Research Project HKZYY-2024-24Hongkou District Key Specialty and Weak Specialty Construction Project of Integrated Chinese and Western Medicine HKGYQYXM-2022-10Medical Innovation Research Project of Shanghai 2022 "Science and Technology Innovation Action Plan" 22Y31920104Shanghai Sailing Program 21YF1444400"Young Talents" Training Plan of Shanghai TCM-Integrated Hospital affiliated to Shanghai University of TCM RCPY0050A
6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) poses a major healthcare burden globally. Traditional Chinese medicine formula Bushen Jianpi (BSJP) recipe shows inhibitory effects on HCC but suffers from low bioavailability. This study aims to develop a BSJP-loaded liposome (BSJP@Lip) for targeted HCC treatment.

methodsBSJP@Lip was prepared using a microfluidic device. Particle characterization included size, morphology, drug loading, encapsulation efficiency, and release kinetics analysis. In vitro cytotoxicity, cellular uptake, apoptosis, and protein expression were evaluated in hepG2, Smmc-7721, and hepa 1-6 hepatic cancer cell lines treated with BSJP@Lip.

resultsBSJP@Lip nanoparticles showed a uniform spherical shape with an average size of 50 nm and zeta potential at around -2.24 mV. They significantly inhibited cell viability and induced apoptosis in a dose-dependent manner compared with traditional decoction formulations. Enhanced cellular uptake of BSJP@Lip increased the expression of proinflammatory factors IL-18 and NLRP3.

conclusionBSJP@Lip nanoparticles were found to be efficiently internalized by hepatic cancer cell lines, resulting in a dose-dependent inhibition of cell viability and induction of apoptosis. This effect was accompanied by the upregulation of IL-18 and NLRP3.

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalLiver NeoplasmsApoptosisCell Line, TumorCell SurvivalDrug LiberationHep G2 CellsHumansLiposomesNanoparticlesParticle SizeDrugs, Chinese HerbalLiposomesBushen JianpiHepatocellular carcinomainflammationliposomenanoparticlestraditional Chinese medicinetreatment.

Identifiers

PMID39289947

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.